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Abstract In this update of our 2005 document, we used an
evidence-based approach whenever possible to formulate
recommendations, emphasizing the results of controlled
trials concerning the best use of antiemetic agents for the
prevention of emesis and nausea following anticancer
chemotherapies of high emetic risk. A three-drug combi-
nation of a 5-hydroxytryptamine type 3 receptor (5-HT3)
receptor antagonist, dexamethasone, and aprepitant begin-
ning before chemotherapy and continuing for up to 4 days
remains the standard of care. We address issues of dose,
schedule, and route of administration of five selective 5-
HT3 receptor antagonists. We conclude that, for each of
these five drugs, there is a plateau in therapeutic efficacy
above which further dose escalation does not improve
outcome. In trials designed to prove the equivalence of
palonosetron to ondansetron and granisetron, palonosetron
proved superior in emesis prevention, while adverse effects
were comparable. Furthermore, for all classes of antiemetic
agents, a single dose is as effective as multiple doses or a
continuous infusion. The oral route is as efficacious as the
intravenous route of administration.
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Introduction
A selective antagonist to the serotonin (5-hydroxytryptamine
type 3 receptor (5-HT3)) [17, 24, 47] combined with
dexamethasone and the neurokinin-1 (NK1) receptor
antagonist aprepitant has become the standard of care to
prevent emesis following chemotherapy of high emetic
risk. Although ondansetron, granisetron, tropisetron, and
dolasetron differ in receptor specificity, potency, and
plasma half-life [3, 47], each has demonstrated equivalent
efficacy and adverse effects when used to prevent emesis
following chemotherapy of high emetic risk. Recently, the
5-HT3 antagonist palonosetron has shown superior efficacy to
granisetron when both were used in combination with
dexamethasone in a trial designed to show equivalence [52].
This is the first conclusive demonstration of a meaningful
efficacy difference when two 5-HT3 antagonists were
compared. Despite these successes and widespread accep-
tance and availability of these agents, a number of
controversies persist regarding the best way to use these
agents in practice.
The “no emesis” rate for 5 days (120 h) following
chemotherapy is the primary endpoint of modern antiemetic
trials. Researchers also consider control during the initial
24 h after chemotherapy (acute emesis) and prevention
from 24 to 120 h (delayed emesis) as additional parameters
to be evaluated in antiemetic drug trials. This discussion
will review issues of dose, schedule, and route of
administration of five selective 5-HT3 receptor antagonists
for the prevention of acute emesis caused by chemotherapy
of high emetic risk. We also address issues of dose,
schedule, and route of administration of dexamethasone
and the NK1 antagonist aprepitant. We make recommenda-
tions for the use of these agents. This document relies
heavily on this group's 2005 manuscript presenting our
consensus synthesis and recommendations [37]. Many
sections not requiring updating have been repeated here.
Dose of 5-HT3 receptor antagonists
The panel concluded that, despite preclinical differences,
the 5-HT3 receptor antagonists are characterized clinically
by a threshold effect for response, a modest dose-response
curve, and a plateau in therapeutic efficacy extending over a
several-fold range in dose. The therapeutic implications of
these conclusions are that a higher dose or longer exposure
is not necessarily better and that breakthrough emesis
following the administration of a 5-HT3 receptor antagonist
is more likely mediated by another mechanism rather than
inadequate 5-HT3 receptor blockade [1, 2, 7, 8, 21, 56]. For
ondansetron and granisetron, there is variability in the
“approved” single doses for the prevention of acute emesis
following chemotherapy of high emetic risk. In the USA,
the approved dose of ondansetron (32 mg or approximately
0.45 mg/kg) is fourfold that of Europe (8 mg), while for
granisetron, exactly the opposite is true with a 1-mg
(0.01 mg/kg) dose in the USA vs a 3-mg (0.04 mg/kg)
dose in Europe.
In view of the above considerations, analysis of the
literature regarding dose was performed for the five 5-HT3
receptor antagonists in widest use. Both dose-response
studies of individual agents and comparative trials between
agents were considered. Study designs that incorporate
issues of schedule are addressed below. Cisplatin serves as
a paradigm for chemotherapy of high emetic risk. More-
over, cisplatin causes severe emesis in all patients who
receive it at all doses in clinical use [39]. For these reasons,
cisplatin has become the standard emetic stimulus in
clinical trials of antiemetic agents. Further, all agree that
an agent that lessens or prevents emesis following cisplatin
will at least be as effective with other chemotherapeutic
agents of similar or lesser emetic potential. Randomized
studies have demonstrated the effectiveness of 5-HT3
receptor antagonists for the prevention of acute emesis
following cisplatin [7, 9, 19, 42, 53, 55]. Furthermore, the
addition of dexamethasone consistently improved efficacy
compared to a 5-HT3 receptor antagonist alone, establishing
this combination as a standard for patients receiving
cisplatin-based therapy [25, 49]. Dose-ranging studies of
these agents demonstrate a dose-response curve consistent
with the conclusions discussed earlier [16, 17, 34, 35, 38,
49, 54, 57, 59]. There are conflicting data regarding the
optimal single dose of ondansetron for prevention of acute
emesis from cisplatin. While a study published by Beck et
al. demonstrated that a 32-mg dose was superior to 8 mg,
particularly in patients receiving high-dose cisplatin
(>100 mg/m2); a similarly designed study by Seynaeve
showed that the 8-mg dose was equally effective [4, 53]. In
both studies, a single dose was equivalent to multiple dose
schedules. Studies of the Italian Group for Antiemetic
Research (IGAR) and from Ruff et al. also show a single 8-
mg ondansetron equivalent to either a 32-mg ondansetron
dose or 3 mg of granisetron, respectively [29, 51].
For granisetron, the evidence from two dose-response
studies and comparative trials against ondansetron supports
a dose of 0.01 mg/kg (commonly given as a 1-mg fixed
dose) [45, 49, 54]. The dose-ranging studies of Navari and
Riviere demonstrate that doses of 0.002 or 0.005 mg/kg are
suboptimal while there is an effectiveness plateau above
0.01 mg/kg with a clinically insignificant higher no-emesis
rate, at 0.04 mg/kg [46, 49]. The comparative trial by
Navari supports the 0.01-mg/kg dose, with identical no-
emesis rates for 0.01 vs 0.04 mg/kg in comparison to an
approved and effective multiple-dose schedule of ondanse-
tron (0.15 mg/kg for three doses) [46].
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The dose-ranging study of Van Belle and the compara-
tive trial by Marty both support a 5-mg single-dose
administration of tropisetron as effective in highly emeto-
genic cisplatin-based chemotherapy, with the study of Van
Belle suggesting no further improvement in efficacy at dose
levels up to 40 mg [43, 59]. Dose-ranging studies of
dolasetron did not define the lowest effective dose while the
subsequent comparative trial of Hesketh supports a dose
level of 1.8 mg/kg as effective, with no evidence of
clinically significant improvement in efficacy at 2.4 mg/kg
[27, 36, 57].
A dose-ranging study of palonosetron in patients receiving
chemotherapy of high emetic risk (97% received cisplatin)
tested intravenous doses from 0.0003 to 0.09 mg/kg and
identified 0.003 and 0.0.01 mg/kg as the lowest effective
palonosetron doses [11]. Three subsequent randomized trials
compared a 0.25-mg fixed palonosetron dose, a 0.75-mg
fixed palonosetron dose, and a standard comparator of either
intravenous ondansetron 32 mg [1, 13] or intravenous
dolasetron 100 mg [10]. The three studies confirmed the
effectiveness and safety of palonosetron and showed no
incremental benefit by increasing the single intravenous
dose from 0.25 to 0.75 mg. A single intravenous dose of
0.25 mg of palonosetron is preferred and, at present, is
the dose approved by regulatory authorities for the
treatment of individuals receiving chemotherapy of high
emetic risk. A 0.5-mg oral dosage form of palonosetron
is available.
Dose of dexamethasone
A range of doses of dexamethasone, given either alone or in
combination with a 5-HT3 receptor antagonist, have been
tested as antiemetics. Many of these studies utilized a single
20-mg dose. The IGAR group has reported a comparison
study of dexamethasone dosages ranging from 4 to 20 mg
in patients receiving cisplatin [30]. They recommended a
single 20-mg dose before chemotherapy based on their
observations that the 20-mg dose had the highest numerical
efficacy, and there was no difference in adverse effects
among the doses tested [30].
The concomitant use of aprepitant, however, led to a
change in the recommended dose of dexamethasone in
clinical trials. The initial studies, which demonstrated
improved antiemetic effects using aprepitant in combination
with 5-HT3 antagonists and dexamethasone, administered
dexamethasone at a 20-mg oral dose without difficulty [6,
44]. A pharmacokinetic study in healthy subjects found that
aprepitant increased dexamethasone levels approximately
twofold [5]. Because the differential exposure to dexameth-
asone could “theoretically confound the interpretation of
the efficacy of aprepitant,” a reduction of the oral
dexamethasone dose was made in the aprepitant arms of
the randomized trials comparing a three-drug aprepitant
regimen to the standard dexamethasone plus the ondanse-
tron regimen [26, 48]. A 12-mg oral dose was given before
cisplatin in the aprepitant arms in these studies. Although
other dexamethasone doses may be appropriate, the 12-mg
oral dose tested in two phase III studies [28, 48] is
recommended.
Dose of aprepitant
Aprepitant is the first of a class of drugs that potently
and selectively block the NK1 neurotransmitter receptor,
the binding site of the regulatory peptide substance P. For
the prevention of acute emesis following cisplatin, a
randomized study evaluated oral pre-chemotherapy doses
of aprepitant from 40 to 375 mg and concluded that a
single 125-mg oral dose had “the most favorable benefit-
risk profile [6].” This 125-mg dose was used in the
randomized phase III comparison studies of aprepitant,
and it is the only oral dose that has been approved by
regulatory authorities. Although other aprepitant doses
may be appropriate, the 125-mg oral aprepitant dose tested
in two phase III studies [28, 48] is recommended. An
intravenous (IV) formulation of aprepitant, fosaprepitant,
is available at a dose of 115 mg [8, 40, 59].
Schedule of administration of 5-HT3 antagonist antiemetics
If given at an effective dose, a single dose provides
adequate 5-HT3 receptor blockade for prevention of
acute emesis. Clinical implications of this fact are that
the administration of multiple doses is unnecessary and
that breakthrough emesis during the first 24 h is likely
related to other mediators/receptors. Multiple doses will
only provide a better therapeutic outcome if the initial
dose is suboptimal or if optimal therapeutic efficacy was
dependent on either the plasma half-life or duration of
receptor blockade during the acute phase. Substantial
evidence supports these conclusions, particularly with
ondansetron, the first 5-HT3 receptor antagonist devel-
oped. Early clinical trials of intravenous ondansetron
with cisplatin explored a variety of schedule- related
issues, including variable dosing intervals, number of
doses, and schedules incorporating continuous infusion
[22, 50]. In general, these studies demonstrated that
shortening the dosing interval or increasing the number
of doses did not improve efficacy. A continuous-infusion
schedule following an 8-mg intravenous bolus was also
found to be effective [42]. However, as demonstrated in
the subsequent studies of Beck and Seynaeve, multiple-
dose administration did not improve outcomes [4, 53].
Based on these observations, development of the other
5HT3 antagonists quickly evolved into determining
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optimal levels for intravenous single-dose administration.
The recommended single doses of five 5-HT3 receptor
antagonists are presented in the table.
Route of administration
Clinical outcomes with oral administration of 5-HT3
receptor antagonists and dexamethasone are equivalent to
intravenous administration. Since oral administration is
generally simpler and less resource-intensive, this route is
preferable if the gastrointestinal tract is intact and compli-
ance is assured. As a class, 5-HT3 antagonists exhibit good
bioavailability when administered by the oral route, and the
effectiveness of oral agents is equivalent to intravenous
formulations. We recommend the administration of selec-
tive 5-HT3 antagonists by the oral route whenever
appropriate. In all phase III studies, comparing oral 5-HT3
antagonists with intravenous formulations of antiemetics to
treat cisplatin-induced emesis, control rates are comparable
[15, 20].
Delayed emesis and nausea with chemotherapy of high
emetic risk
Among the chemotherapy agents with high emetic risk,
reliable data on the potential for delayed emesis is only
available with cisplatin. Placebo-controlled trials have
noted delayed emesis developing in 43–89% of patients
following a variety of cisplatin doses [33]. A number of
clinical factors have been identified as having value in
predicting the development of delayed emesis. Female
gender, higher cisplatin dose, and emesis during the first
24 h after chemotherapy are all associated with a higher risk
of delayed emesis [23].
There is considerable evidence for the value of
dexamethasone and the NK1 receptor antagonist aprepi-
tant in preventing cisplatin-induced delayed emesis. A
meta-analysis of results from 5,613 patients who received
highly or moderately emetic chemotherapy for multiple
types of cancer in 32 studies indicated that dexametha-
sone was superior to placebo or no treatment for complete
protection from delayed emesis (OR=2.06;95% CI 1.58–
2.34). In the subset of patients just receiving highly
emetic chemotherapy, dexamethasone was also superior
to placebo or no treatment (OR=1.93; 95% CI 1.58–2.34)
[31].
The NK1 receptor antagonist aprepitant has also
demonstrated significant activity in preventing cisplatin-
induced delayed emesis. Three double-blind, phase III
trials have evaluated the activity of aprepitant in prevent-
ing cisplatin-induced emesis [28, 32, 48]. The initial two
trials had an identical study design and evaluated the
control of delayed emesis as a secondary endpoint [28,
48]. During the delayed phase (days 2–5), patients
received aprepitant on days 2 and 3 combined with
dexamethasone on days 2–4 or dexamethasone alone on
days 2, 3, and 4. Delayed complete response rates on the
aprepitant and standard arms were 75% and 68%,
compared with 56% and 47% in the two studies,
respectively. Different antiemetic regimens were used for
acute prophylaxis in these two trials with patients
receiving aprepitant achieving superior control of emesis
compared to the control group of ondansetron and
dexamethasone alone. Thus, one can question whether a
component of the improved efficacy of the aprepitant-
containing arms during the delayed phase was due to a
carryover effect from the different control rates on day 1.
A subsequent analysis of the combined database from
these two phase III trials strongly supported the conclu-
sion that aprepitant provided protection against delayed
vomiting regardless of the response in the acute phase
[18]. In patients with acute vomiting, the proportion of
patients with delayed vomiting was 85% and 68% on the
control and aprepitant arms, respectively. In patients with
no acute vomiting, the proportion with delayed vomiting
was 33% and 17% on the control and aprepitant arms,
respectively.
A third phase III trial conducted in patients receiving
cisplatin used an identical study design to the other two
phase III aprepitant trials with the exception that ondanse-
tron was continued on days 2, 3, and 4 on the control arm
[32]. Superior control of delayed emesis with an 11%
numerical improvement was noted on the aprepitant vs
control arm with delayed complete response rates of 74%
and 63%, respectively (P=0.004). A subsequent meta-
analysis incorporating the data from all three aprepitant
phase III trials revealed an absolute difference in complete
control and no significant nausea during the delayed period
(days 2–5) of 18% and 10%, respectively, favoring the
aprepitant arms [14].
The 5-HT3 receptor antagonists dolasetron, granisetron,
ondansetron, and tropisetron have demonstrated minimal
activity in the prevention of cisplatin-induced delayed
emesis. Trials have compared granisetron or ondansetron
combined with dexamethasone with dexamethasone alone
[12, 41, 58]. In all three studies, a total of 1,022 patients, the
combination regimen was no better than dexamethasone
alone. Data from two phase III trials with the 5-HT3 receptor
antagonist palonosetron, however, suggest that this agent
lessens cisplatin-induced delayed emesis. In a trial compar-
ing palonosetron, either 0.25 or 0.75 mg, with 32 mg of
ondansetron, all given as a single agent IV prior to cisplatin-
based chemotherapy, both palonosetron doses resulted in
numerically better control of delayed emesis compared to
ondansetron [2]. Complete response rates were 45%, 48%,
and 39% in the palonosetron 0.25 and 0.75 mg and
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ondansetron arms, respectively. A second phase III trial com-
pared single-dose palonosetron, 0.75 mg IV with granisetron,
40 μg/kg IV, both combined with dexamethasone before
cisplatin, in patients receiving cisplatin [52]. Patients also
received dexamethasone 8 mg IVon days 2 and 3. Control of
delayed emesis was significantly better with palonosetron
compared to granisetron. Rates of no delayed emesis or
antiemetic rescue were 54% vs 41% on the palonosetron and
granisetron arms, respectively (P=0.0012). In neither of the
phase III trials of palonosetron with cisplatin-based chemo-
therapy was an NK1 receptor antagonist included. Thus, it
remains unclear whether the differences in antiemetic
efficacy between palonosetron and granisetron or ondanse-
tron would have persisted in the presence of a NK1
antagonist.
Given the dependence of delayed emesis on control
during the initial 24 h after chemotherapy, the panel
recommends that optimal acute antiemetic prophylaxis be
employed. For cisplatin and other chemotherapy agents
with high emetic risk, this should include the three-drug
combination of aprepitant, a 5-HT3 receptor antagonist and
dexamethasone. In head-to-head comparisons between
palonosetron and either granisetron or ondansetron, delayed
emesis prevention was improved whether or not dexameth-
asone was given in addition. The combination of aprepitant
and dexamethasone is recommended to prevent delayed
emesis. Aprepitant should be used as a single 80-mg oral
dose on days 2 and 3. No studies have been published
evaluating the optimal dose of dexamethasone for the
prevention of delayed emesis.
Consensus statements
Recommendation for the prevention of nausea
and vomiting following chemotherapy of high emetic risk
To prevent acute and delayed vomiting and nausea
following chemotherapy of high emetic risk, we recom-
mend a multiday drug regimen including a 5-HT3 receptor
antagonist, dexamethasone, and aprepitant beginning before
chemotherapy
– MASCC level of consensus: high
– MASCC level of confidence: high
– ESMO level of evidence: I
– ESMO grade of recommendation: A
Patients are at risk for delayed emesis and must receive
prophylactic antiemetics for 2 to 3 days following chemo-
therapy (Table 1).
Consensus principles of 5-HT3 receptor antagonist use
to prevent acute and delayed nausea and emesis
Use the lowest tested fully effective dose.
No schedule better than a single dose beginning before
chemotherapy.
Adverse effects of these agents are comparable.
Intravenous and oral formulations are equally effective
and safe.
Table 1 Agents to prevent vomiting and nausea after high emetic risk chemotherapy
Agents Single daily dose MASCC
consensus
MASCC
confidence
ESMO type
of evidence
ESMO grade of
recommendation
5-HT3 receptor antagonists
Palonosetron IV: 0.25 mg High Mod II A
Dolasetron Oral:100 mg IV:100 mg or 0.18 mg/kg High Mod I A
High I
Granisetron Oral: 2 mg IV: 1 mg or 0.01 mg/kg High High I A
High High I A
Ondansetron Oral: 24 mg IV: 8 mg or 0.15 mg/kg Mod High I A
High High I A
Tropisetron Oral or IV: 5 mg High Mod I A
Dexamethasone
Dexamethasone Pre-chemotherapy Oral or IV: 12 mg High High I A
Post-chemotherapy Days 2, 3, 4 Oral or IV: 8 mg
NK1 receptor antagonist
Aprepitant Pre-chemotherapy Oral: 125 mg IV: 115 mg High High I A
Post-chemotherapy Days 2, 3 Oral: 80 mg
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Give with dexamethasone and aprepitant beginning
before chemotherapy.
– MASCC level of consensus: high
– MASCC level of confidence: moderate
– ESMO level of evidence: I
– ESMO level of confidence: A
Summary and conclusions
Consensus recommendations for the doses of each
specific antiemetic agent used to prevent acute emesis
from chemotherapy of high emetic risk are presented in
Table 1. Whenever possible, these recommendations
represent an analysis of literature using an evidence-
based approach. In addition, they also reflect the input of
the discussants and participants during this consensus
conference.
The 5-HT3 receptor antagonists, dexamethasone, and the
NK1 receptor antagonists have substantially improved our
ability to prevent acute and delayed emesis and nausea
caused by chemotherapy of high emetic risk. These three
classes used in combination are the standard of care in
patients receiving high emetic risk chemotherapy including
cisplatin. Nevertheless, many patients continue to experi-
ence vomiting and nausea despite receiving optimal
prophylaxis. It is likely that these episodes are mediated
through mechanisms unaffected by the combined effects of
dexamethasone along with 5-HT3 and NK1 receptor
blockade. Further improvements can only occur after a
better understanding of the underlying pathophysiology of
emesis caused by chemotherapy allows us to create new
drugs that more effectively silence the neural signals that
trigger nausea and vomiting. Only then will we be able to
eliminate emesis caused by cancer treatment. In the
meantime, using the available agents according to treat-
ment guidelines, beginning before the first dose of
chemotherapy and continuing for 4 days, is the best
strategy to maximally lessen the burden of nausea and
emesis for every person receiving chemotherapy of high
emetic risk.
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